The Asia-Pacific anti-nuclear antibody test market is expected to reach USD 394.58 million by 2025, from USD 211.03 million in 2017 growing at a CAGR of 8.2% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.
The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection.
The key market players for Asia-Pacific anti-nuclear antibody test market are listed below;
Bio-Rad Laboratories, Inc.
Alere, Inc.
Trinity Biotech
Thermo Fisher Scientific Inc.
Antibodies Inc.
EUROIMMUN AG
Immuno Concepts
The market is further segmented into;
Product
Test
Disease
End-user
The Asia-Pacific anti-nuclear antibody test market is segmented on the basis of product into assay kits & reagents, systems, and software. In 2018, assay kits & reagents is expected to dominate the Asia-Pacific anti-nuclear antibody test market with 54.8% market share and is expected to reach USD 219.73 million by 2025, with the highest CAGR of 8.5% in the forecast period 2018 to 2025.
The Asia-Pacific anti-nuclear antibody test market is segmented on the basis of test into indirect immunofluorescence, ELISA, and multiplex testing. In 2018, indirect immunofluorescence is expected to dominate the Asia-Pacific anti-nuclear antibody test market with 53.0% market share and is expected to reach USD 200.17 million by 2025, with the CAGR of 7.6% in the forecast period 2018 to 2025. However, multiplex testing market segment is expected to grow at the highest CAGR of 9.5% in the forecast period, and is expected to reach USD 77.98 million in 2025 from USD 38.15 million in 2017.
The Asia-Pacific anti-nuclear antibody test market is segmented on the basis of disease into systemic lupus erythematosus, Sj?gren?s syndrome, rheumatoid arthritis, scleroderma, polymyositis, and others. In 2018, systemic lupus erythematosus is expected to dominate the Asia-Pacific anti-nuclear antibody test market with 33.6% market share and is expected to reach USD 138.17 million by 2025, with the highest CAGR of 8.9% in the forecast period 2018 to 2025.
The Asia-Pacific anti-nuclear antibody test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, and others. In 2018, hospitals is expected to dominate the Asia-Pacific anti-nuclear antibody test market with 48.3% market share and is expected to reach USD 193.92 million by 2025, with the highest CAGR of 8.5% in the forecast period 2018 to 2025.
Based on geography, the Asia-Pacific anti-nuclear antibody test market is segmented into geographical regions, such as,
Germany,
China,
Japan,
India,
South Korea,
Australia,
Thailand,
Malaysia,
Singapore,
Indonesia,
Philippines,
Rest of Asia-Pacific
Covered in this report
The report covers the present scenario and the growth prospects of the Asia-Pacific anti-nuclear antibody test for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst?s time when you purchase this market report. Details are provided within the report.
